

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

MEDIMMUNE INC /DE
Form 10-Q
November 14, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH

For the quarterly period ended September 30, 2001

Commission File No. 0-19131

MedImmune, Inc.
(Exact name of registrant as specified in its charte

Delaware
(State or other jurisdiction of
incorporation or organization)

52-1555759
(I. R. S. Employer
Identification No.)

35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (301) 417-0

Indicate by check mark whether the Registrant (1) has filed all reports required to be f
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that
such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes

As of September 30, 2001, 214,044,267 shares of Common Stock, par value \$0.01 per share, were ou

MEDIMMUNE, INC.
Index to Form 10-Q

Part I Financial Information

Item 1. Financial Statements

Consolidated Balance Sheets
Consolidated Statements of Operations
Condensed Consolidated Statements of Cash Flows

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Notes to Consolidated Financial Statements

- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
- Item 3. Quantitative and Qualitative Disclosures about Market Risk

Part II Other Information

- Item 1. Legal Proceedings
- Item 2. Changes in Securities
- Item 3. Defaults upon Senior Securities
- Item 4. Submission of Matters to a Vote of Security Holders
- Item 5. Other Information
- Item 6. Exhibits and Reports on Form 8-K

Synagis, CytoGam, Ethyol, RespiGam, NeuTrexin, and Hexalen are registered trademarks of